A patient with an A1c of 9.6% who is taking metformin 100 mg twice daily, Trijardy XR (sitagliptin/metformin extended‑release) 25/5/1000 mg, and insulin glargine (Lantus) – what is the next step to improve glycemic control?

Next Step: Optimize Basal Insulin Dosing First

The immediate priority is to titrate the Lantus (insulin glargine) dose upward using an evidence-based algorithm—increase by 2 units every 3 days until fasting plasma glucose reaches target without hypoglycemia. 1

Why Insulin Titration Comes First

Your patient is already on basal insulin (Lantus) but with an A1c of 9.6%, the current dose is clearly inadequate. The 2025 ADA Standards of Care explicitly state that when A1c remains above goal in patients already on basal insulin, the first step is to assess adequacy of the insulin dose at every visit 1. Before adding more medications or switching to prandial insulin, you must ensure the basal insulin is properly titrated.

The Titration Algorithm

• Increase Lantus by 2 units every 3 days until fasting plasma glucose reaches the individualized target (typically 80-130 mg/dL)
• Monitor for hypoglycemia: If it occurs without clear cause, reduce dose by 10-20%
• Set a specific fasting glucose goal and titrate systematically 1

Critical Medication Review Required

There's a major dosing error in your current regimen: You list metformin 100mg BID, but therapeutic metformin dosing starts at 500mg and goes up to 2000-2550mg daily 1. This is either a transcription error or the patient is severely under-dosed on metformin. If truly on 100mg BID (200mg total), this provides essentially no glycemic benefit.

Trijardy XR already contains metformin 1000mg (along with empagliflozin 25mg and linagliptin 5mg). Adding separate metformin creates:

• Potential for metformin overdose if the "100mg" is actually a higher dose
• Medication redundancy and confusion
• Increased GI side effects risk

Immediate Action Steps

1. Clarify the metformin dose - if it's actually 1000mg BID, the patient is getting 3000mg total daily (2000mg from Trijardy XR + 1000mg from separate metformin), which exceeds standard dosing
2. Consolidate metformin dosing - eliminate the separate metformin if Trijardy XR provides adequate metformin coverage
3. Titrate Lantus aggressively using the algorithm above

When to Consider Adding Prandial Insulin

Only after optimizing basal insulin should you consider prandial insulin. The guidelines specify looking for "overbasalization" signals 1:

• Large bedtime-to-morning glucose differential
• Large postprandial-to-preprandial glucose differential
• Hypoglycemia (aware or unaware)
• High glucose variability
• Fasting glucose at goal but A1c still elevated

If these signals appear, add prandial insulin: Start with 4 units before the largest meal or 10% of basal dose, then titrate by 1-2 units or 10-15% based on postprandial readings 1.

Alternative: Consider GLP-1 RA Addition

The guidelines note that if A1c remains above goal in patients on basal insulin who are not already on a GLP-1 RA, adding one should be considered 1. Since your patient is on Trijardy XR (which contains a DPP-4 inhibitor, linagliptin), adding a GLP-1 RA would provide complementary incretin-based therapy with superior A1c lowering and weight benefits compared to DPP-4 inhibitors.

Research supports this: Studies show GLP-1 RAs added to insulin + metformin produce greater A1c reductions than DPP-4 inhibitors, with A1c drops of 2.2-3.1% from baselines around 10% 2, 3. However, you cannot use both a DPP-4 inhibitor and GLP-1 RA together—they work on the same pathway and combining them provides no additional benefit.

If Choosing the GLP-1 RA Route

• Discontinue Trijardy XR (loses the linagliptin component)
• Replace with separate empagliflozin 25mg (maintains SGLT2 inhibitor benefit)
• Add a GLP-1 RA with proven cardiovascular benefit (semaglutide, dulaglutide, or liraglutide)
• Continue metformin at appropriate dose (1500-2000mg daily)
• Continue and titrate Lantus

Common Pitfalls to Avoid

• Therapeutic inertia: Don't wait months to intensify—reassess every 3-6 months and adjust 1
• Polypharmacy without optimization: Adding more drugs before maximizing existing ones leads to side effects without benefit
• Ignoring medication reconciliation: The metformin duplication issue exemplifies why careful review matters
• Premature prandial insulin: Adding mealtime insulin before optimizing basal insulin increases hypoglycemia risk and complexity 4

Bottom Line Algorithm

1. Immediately: Clarify and consolidate metformin dosing
2. Week 1-6: Titrate Lantus by 2 units every 3 days to fasting glucose goal
3. Week 6-12: If A1c remains >7.5% despite optimized basal insulin:
   • Option A: Add prandial insulin (4 units with largest meal)
   • Option B: Switch Trijardy XR to empagliflozin alone + add GLP-1 RA
4. Ongoing: Monitor for hypoglycemia, adjust doses by 10-20% if occurs

The research consistently shows that patients with A1c 9-11% can achieve reductions of 2-4% with proper insulin titration and combination therapy 5, 6, 4, making your patient's goal of A1c <7% achievable within 3-6 months with aggressive but safe management.